Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Should FDA Fast Track Status for Nipocalimab in Lupus Reshape Johnson & Johnson’s (JNJ) Immunology Ambitions?
Johnson & Johnson received FDA Fast Track designation for nipocalimab to treat systemic lupus erythematosus, underscoring the importance of its FcRn-blocking platform in autoantibody-driven diseases. This development strengthens J&J’s pipeline as it navigates biosimilar pressures on STELARA and ongoing legal exposures. While encouraging for future revenue, investors must still consider broader market pressures and the company’s financial forecast, including a projected 4.7% yearly revenue growth to $104.1 billion by 2028.